Inari Medical initiated with a Buy at Needham

Needham initiated coverage of Inari Medical with a Buy rating and $72 price target. The analyst is positive on the company’s position as a leader in the large and underpenetrated venous thrombectomy market, noting that its new product launches, international expansion, and the LimFlow acquisition should sustain strong growth for Inari Medical. Needham adds that it sees rapid improvement in the company’s operating margin and EPS in 2025 and beyond while noting that its valuation is attractive considering its high teens or better revenue growth.